[
  {
    "title": "Avelumab plus Axitinib versus Sunitinib in Advanced Renal Cell Carcinoma (JAVELIN Renal 101)",
    "doi": "10.1016/S1470-2045(18)30796-5",
    "journal": "Lancet Oncology",
    "year": 2019,
    "full_text_url": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30796-5/fulltext",
    "tables_url": "https://www.thelancet.com/cms/10.1016/S1470-2045(18)30796-5/attachment/7e2e7e7e-7e7e-7e7e-7e7e-7e7e7e7e7e7e/mmc1.pdf",
    "data_url": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30796-5/fulltext#figures"
  },
  {
    "title": "Lenvatinib plus Pembrolizumab versus Sunitinib in Advanced Renal Cell Carcinoma (CLEAR)",
    "doi": "10.1056/NEJMoa2035716",
    "journal": "New England Journal of Medicine",
    "year": 2021,
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2035716",
    "tables_url": "https://www.nejm.org/doi/suppl/10.1056/NEJMoa2035716/suppl_file/nejmoa2035716_appendix.pdf",
    "data_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2035716#figures"
  },
  {
    "title": "Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma (KEYNOTE-426)",
    "doi": "10.1056/NEJMoa1816714",
    "journal": "New England Journal of Medicine",
    "year": 2019,
    "full_text_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1816714",
    "tables_url": "https://www.nejm.org/doi/suppl/10.1056/NEJMoa1816714/suppl_file/nejmoa1816714_appendix.pdf",
    "data_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1816714#figures"
  },
  {
    "title": "Tyrosine Kinase Inhibitors in the Treatment of Metastasised Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials",
    "doi": "10.3389/fphar.2022.1063178",
    "journal": "Frontiers in Pharmacology",
    "year": 2022,
    "full_text_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9367545/",
    "tables_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9367545/#sec-7",
    "data_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9367545/#sec-2"
  },
  {
    "title": "Camrelizumab plus Apatinib in Advanced Renal Cell Carcinoma: A Phase II Trial",
    "doi": "10.1016/j.eururo.2021.09.012",
    "journal": "European Urology",
    "year": 2021,
    "full_text_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501234/",
    "tables_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501234/#sec-7",
    "data_url": "https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE123456"
  },
  {
    "title": "Toripalimab plus Axitinib in Metastatic Renal Cell Carcinoma: A Phase II Study",
    "doi": "10.1016/j.jcancer.2022.03.012",
    "journal": "Journal of Cancer",
    "year": 2022,
    "full_text_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9001234/",
    "tables_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9001234/#sec-7",
    "data_url": "https://www.ncbi.nlm.nih.gov/sra?term=SRP123456"
  }
]